Trial reportBMC ophthalmology2026
Subconjunctival autologous platelet-rich plasma as an adjunctive therapy for limbal-scleral ischemia following acute ocular burns: a prospective randomized pilot trial.
Trial report in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the feasibility and short-term outcomes of subconjunctival injection of autologous platelet-rich plasma (PRP) as an adjunct to topical PRP for limbal-scleral ischemic area (LSIA) following acute ocular burns.
methodsThis prospective randomized pilot study included patients with LSIA within three weeks of chemical or thermal ocular burns. Sixteen eyes of 16 patients were randomized using permuted block randomization into two groups. Both groups received standard medical therapy including topical PRP eye drops. The intervention group additionally received a single session of subconjunctival PRP injection. Limbal-scleral ischemic area (LSIA) was quantified using ImageJ. Best-corrected visual acuity (BCVA) at 3 months was analyzed as a primary outcome. The secondary outcome was change in LSIA size and time to complete revascularization.
resultsSixteen eyes of 16 patients (mean age 35.37 ± 11.42 years; all male) were included. Mean BCVA improved from 1.44 ± 0.70 to 1.07 ± 0.95 logMAR (p > 0.05). Baseline LSIA was 57.03 ± 28.68 mm
conclusionSubconjunctival autologous PRP appears feasible and safe as an adjunct to topical PRP in acute ocular burns. However, no significant benefit in LSIA healing was demonstrated, and larger controlled trials are required to determine efficacy.
trial registrationThis clinical trial was retrospectively registered with the Iranian Registry of Clinical Trials (IRCT; registration number: IRCT20231219060471N3 on July 30, 2026.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.